Clicky

Allogene Therapeutics, Inc.(ALLO)

Description: Allogene Therapeutics is a clinical stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer. Led by a world-class management team with significant experience in cell therapy, we are developing a pipeline of “off-the-shelf” CAR T cell therapy candidates with the goal of delivering readily available cell therapy faster, more reliably and at greater scale to more patients.


Keywords: Biotechnology Cancer Life Sciences Stem Cell Cell Therapy Cell Biology Therapies For Cancer Adoptive Cell Transfer

Home Page: www.allogene.com

ALLO Technical Analysis

210 East Grand Avenue
South San Francisco, CA 94080
United States
Phone: 650 457 2700


Officers

Name Title
Dr. Arie S. Belldegrun F.A.C.S., FACS, M.D. Co-Founder & Exec. Chairman
Dr. David D. Chang M.D., Ph.D. Co-Founder, Pres, CEO & Director
Mr. Joshua A. Kazam Co-Founder & Director
Dr. Eric Thomas Schmidt Ph.D. Chief Financial Officer
Dr. Alison Moore Ph.D. Chief Technical Officer
Mr. Veer Bhavnagri Gen. Counsel & Compliance Officer
Dr. Rafael G. Amado M.D. Exec. VP of R&D
Ms. Barbra Sasu Chief Scientific Officer
Mr. Stephen Cheng Chief Information Officer
Ms. Christine Cassiano Chief Communications Officer

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 1.5084
Price-to-Sales TTM: 4133.631
IPO Date: 2018-10-11
Fiscal Year End: December
Full Time Employees: 356
Back to stocks